N-[1,1-dimethyl-2-(4-trifluoromethyl-phenyl)-ethyl]-formamide | 182217-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[1,1-dimethyl-2-(4-trifluoromethyl-phenyl)-ethyl]-formamide
• 英文别名: N-[2-methyl-1-[4-(trifluoromethyl)phenyl]propan-2-yl]formamide
• CAS: 182217-79-4
• 化学式: C₁₂H₁₄F₃NO
• 分子量: 245.244
• InChiKey: TZFJSWHCMYZUCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[1,1-dimethyl-2-(4-trifluoromethyl-phenyl)-ethyl]-formamide 在 盐酸 、 水 作用下， 生成 2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-amine
  参考文献：
  名称：

  Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists

  摘要：

  Novel beta(2)-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described. Systematic chemical variations at the phenethylamine residue of these compounds lead to the discovery of compound 6m as potent, full agonist of the beta(2)-adrenoceptor with a high beta(1)/beta(2)-selectivity. Molecular modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the beta(2)-receptor as putative explanation for the high observed selectivity. Further, compound 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5 h. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.013
• 作为产物：
  描述：

  sodium cyanide 、 2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-ol 在 硫酸 、 溶剂黄146 作用下， 生成 N-[1,1-dimethyl-2-(4-trifluoromethyl-phenyl)-ethyl]-formamide
  参考文献：
  名称：

  Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists

  摘要：

  Novel beta(2)-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described. Systematic chemical variations at the phenethylamine residue of these compounds lead to the discovery of compound 6m as potent, full agonist of the beta(2)-adrenoceptor with a high beta(1)/beta(2)-selectivity. Molecular modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the beta(2)-receptor as putative explanation for the high observed selectivity. Further, compound 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5 h. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.013

文献信息

• Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
  申请人：Boehringer Ingelheim Pharma GmbH & Co.KG

  公开号：EP1577306A1

  公开（公告）日：2005-09-21

  Die vorliegende Erfindung betrifft die Verbindungen der allgemeinen Formel 1 worin die Reste R, R1, R2, R3 und A die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel, insbesondere zur Behandlung von entzündlichen und obstruktiven Atemwegserkrankungen.

  本发明涉及一般式1的化合物，其中残基R、R1、R2、R3和A可以具有在权利要求和说明中提及的含义，以及其制备方法和用途作为药物，特别是用于治疗炎症和阻塞性呼吸道疾病。
• Thermal Cleavage of Oxazolidine-4,5-diones to Imines: A Short Synthesis of 3,4-Dihydro-3,3-dimethyl-7-trifluoromethylisoquinoline-2-oxide
  作者：Ronald C. Bernotas、Ginette Adams、Thaddeus R. Nieduzak

  DOI：10.1080/00397919608003751

  日期：1996.9

  Abstract A series of oxazolidine-4,5-diones 2 was thermally cleaved to cyclic imines 3 in excellent yield. This reaction was utilized in an efficient synthesis of a 3,4-dihydroisoquinoline-based nitrone 1b.

  摘要 一系列恶唑烷-4,5-二酮 2 以优异的产率热裂解成环亚胺 3。该反应用于有效合成基于 3,4-二氢异喹啉的硝酮 1b。
• Novel long acting betamimetics for the treatment of respiratory diseases
  申请人：Bouyssou Thierry

  公开号：US20050209227A1

  公开（公告）日：2005-09-22

  The present invention relates to the compounds of general formula 1 wherein the groups R, R 1 , R 2 , R 3 and A may have the meanings given in the claims and specification, processes for preparing them and their use as medicaments, particularly for the treatment of inflammatory and obstructive respiratory complaints.

  本发明涉及一般式1的化合物，其中基团R、R1、R2、R3和A可能具有在权利要求书和说明书中给出的含义，以及制备它们的过程和它们作为药物的用途，特别是用于治疗炎症和阻塞性呼吸疾病。
• NEUE BENZOXAZINONDERIVATE ALS LANGWIRKSAME BETAMIMETIKA ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN
  申请人：BOEHRINGER INGELHEIM INTERNATIONAL GMBH

  公开号：EP1730126B1

  公开（公告）日：2012-01-11
• US7244728B2
  申请人：——

  公开号：US7244728B2

  公开（公告）日：2007-07-17